Notable Friday Option Activity: AMD, LLY, CRL

Eli Lilly saw unusually high options activity with 22,521 contracts traded (≈2.3 million underlying shares), about 60.8% of its one‑month average daily volume, led by 1,039 contracts in the $890 put expiring Feb 20, 2026 (≈103,900 shares). Charles River Laboratories logged 4,986 option contracts (≈498,600 shares), roughly 57.2% of its one‑month average daily volume, driven by 1,900 contracts in the $180 call expiring Mar 20, 2026 (≈190,000 shares). The report highlights these concentrated strikes and expirations as notable flow signals for traders and risk managers.

Analysis

Market structure: The outsized options flows (LLY puts ~2.3M underlying, CRL calls ~498k underlying) equal ~60% of each name’s ADTV, meaning market‑maker delta hedging could move spot 1–5% in short windows. Direct beneficiaries are liquidity providers collecting premium and directional traders who initiated the flow; end investors and index/ETF holders risk short‑term mark‑to‑market volatility. For CRL the call skew implies demand for upside exposure to CRO outsourcing; for LLY the large put interest signals concentrated demand for downside protection or speculative bearish bets.

Risk assessment: Tail risks include regulatory/pricing shocks for LLY (Medicare drug pricing, patent litigation) and client/outsourcing slowdowns for CRL; either could produce >20% idiosyncratic moves. Immediate (days) risk is gamma‑driven volatility around the highlighted expiries (Feb 20 and Mar 20, 2026); short term (weeks) IV re-pricing and earnings/FDA catalysts matter; long term (quarters) fundamentals reassert. Hidden dependency: if flows are dealer‑covered shorts, unwind could flip direction quickly (short squeeze); monitor IV and dealer inventory indicators.

Trade implications: Tactical ideas: use defined‑risk option spreads to exploit directional flow while capping premium spend — e.g., small put spreads on LLY into Feb 20 expiry to hedge or speculate, and call spreads on CRL into Mar 20 for upside exposure. Consider relative trades to isolate idiosyncratic moves (long CRL vs short IQV or long JNJ vs short LLY) sized to beta. Size individual trades to 0.5–2% of portfolio and scale on IV moves >10% or volume >50% ADTV.

Contrarian angles: The market may misread block volume as pure directional conviction; many large single‑strike trades are hedges or synthetics (collars, convertibles). That means price reaction could be overdone (panic selling into puts) or muted if flows are offsetting; historical parallels show single‑strike concentration can either create a squeeze or evaporate when the trade rolls. Unintended consequence: aggressive put buying into LLY could create a dealer short‑stock position that amplifies downside if negative news hits, then reverses violently on positive catalysts.

Key Decisions for Investors

• Establish a defined‑risk bearish hedge on LLY: buy Feb 20, 2026 $890/$850 put spread sizing max premium = 0.5–1.0% of portfolio (target asymmetric payoff if LLY slides >5% into expiry); reduce or close if IV falls >20% or spread cost >2× average intraday premium.
• Initiate a tactical bullish position in CRL: buy Mar 20, 2026 $180/$200 call debit spread sized 0.5–1.5% portfolio (breakeven implies ~+11–14% stock move); take profits if CRL rallies 15–25% or if IV compresses >15% post‑earnings/contract news.
• Implement a pair trade to isolate CRO exposure: go long CRL (1%) and short IQV (0.8%) to neutralize market beta, monitor spread tightening; unwind if spread diverges >10% from 90‑day historical median or after CRL reports a major contract within 30 days.
• Monitor and act on flow/IV triggers: enter/increase sizes only when option volume >50% ADTV persists for 3 consecutive sessions or IV moves ±10%; use these metrics as stop/grow signals rather than headline momentum alone.